此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Risk Factors for Community- and Workplace Transmission of COVID-19

2021年11月29日 更新者:Arne Vasli Lund Søraas、Oslo University Hospital
The project is an epidemiological observational study based on an electronic questionnaire on risk factors for COVID-19 in the community and healthcare setting.

研究概览

详细说明

Summary The data collected will identify real-life risk factors for getting the COVID-19 diagnosis.

The Oslo University Hospital/University of Oslo web-based solution "nettskjema" will be used to collect data and consent forms.

The impact of knowing the risk factors for COVID-19 is tremendous because it can enable governments to conduct more targeted public health measurements than today to reduce the spread of the virus.

Detailed description Research into an ongoing COVID-19 outbreak is difficult because patients are isolated, and supplies of personal protective equipment (PPE) supplies are limited. The risk of transmission to study personal is non-negligible even when PPE is available.

A study design based on an electronic questionnaire and consent from delivered from the Oslo University Hospital/University of Oslo, GDPR (General Data Protection Regulation) compliant "TSD" service has therefore been chosen.

The study will be a case-control study based on a combined electronic consent form and questionnaire that the participants will fill in using a smartphone and electronic identification.

The groups that will be included are:

  • Hospitalized and non-hospitalized patients/persons with COVID-19 at all stages of the disease and after the disease
  • Hospitalized patients without COVID-19
  • Healthcare personal or other groups with an increased risk of COVID-19
  • Healthy volunteers

Participants may be followed with repeated questionnaires prospectively.

Biological samples Biological samples may hold crucial information about the susceptibility to COVID-19 and for susceptibility to the progression of the disease. It is within the scope of the study to analyze such samples from a limited number of participants which will be asked to provide such samples or hospitalized patients that have surplus material. The material will be analyzed with non-genetic methods most suitable to provide such information.

研究类型

观察性的

注册 (预期的)

250000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Oslo、挪威、0424
        • 招聘中
        • Oslo University Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

概率样本

研究人群

The study will be a combined retrospective and prospective case-control study based on a combined electronic consent form and questionnaire that the study groups will fill in using a smartphone and electronic identification.

The groups that will be included are:

  • Hospitalized and non-hospitalized patients/persons with COVID-19 at all stages of the disease and after the disease
  • Hospitalized patients without COVID-19
  • Healthcare personal or other groups with an increased risk of COVID-19
  • Healthy volunteers

Probability sampling will be conducted, but not solely.

描述

Inclusion Criteria:

  • Norwegian adult

Exclusion Criteria:

  • Unable to consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Individuals with COVID-19 infection

Confirmed by routine laboratory diagnosis. All types of COVID-19 disease from asymptomatic carriers to hospitalized patients can be included.

Only subjects >18 years old will be included in the study.

No intervention, only prospective observation of behavior will be conducted by a questionnaire.
Individuals tested for COVID-19 infection with negative test
Confirmed by routine laboratory diagnosis
No intervention, only prospective observation of behavior will be conducted by a questionnaire.
Healthy individuals
Recruitet from the general population
No intervention, only prospective observation of behavior will be conducted by a questionnaire.
Risk groups for COVID-19 exposure
Including, but not limited to healthcare workers.
No intervention, only prospective observation of behavior will be conducted by a questionnaire.
Patients admitted to hospital
Without COVID-19 infection.
No intervention, only prospective observation of behavior will be conducted by a questionnaire.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Rate of COVID-19 infection
大体时间:1 year
Diagnosed with serology or direct viral detection
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年3月27日

初级完成 (预期的)

2025年3月27日

研究完成 (预期的)

2030年3月20日

研究注册日期

首次提交

2020年3月23日

首先提交符合 QC 标准的

2020年3月23日

首次发布 (实际的)

2020年3月25日

研究记录更新

最后更新发布 (实际的)

2021年12月13日

上次提交的符合 QC 标准的更新

2021年11月29日

最后验证

2021年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • REK-124170

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

IPD 计划说明

European GDPR regulations severely limits IPD, but the study will share data to the largest extent possible within GDPR.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅